Results 51 to 60 of about 4,120 (178)

Successful experience of tofacitinib treatment in patients with Fibrodysplasia Ossificans Progressiva

Pediatric Rheumatology Online Journal, 2023
Fibrodysplasia ossificans progressive (FOP) is an ultra-rare genetic disorder that is caused by a mutation in the ACVR1 gene and provokes severe heterotopic ossification.
Irina P. Nikishina, Svetlana V. Arsenyeva, Valeria G. Matkava, Alia N. Arefieva, Mariya I. Kaleda, Alexandr V. Smirnov, Leonid M. Blank, Mikhail M. Kostik   +7 more
doaj   +1 more source

A Simple Cell Culture Assay for Human Prostatic Branching Morphogenesis Spotlights Bone Morphogenetic Protein Signaling as a Therapeutic Target in Benign Prostatic Hyperplasia

The Prostate, Volume 86, Issue 13, Page 1332-1340, September 15, 2026.
ABSTRACT Background Benign prostatic hyperplasia (BPH) leads to prostate enlargement and lower urinary tract symptoms that can resist treatment. A histologic hallmark of BPH is glandular epithelial hyperplasia with new ductal branching morphogenesis. The stromal inductive factors driving tissue morphogenesis may provide new therapeutic targets, but are
Anna S. Pollack, James D. Brooks, Jonathan R. Pollack   +2 more
wiley   +1 more source

BMP‐ACVR1 Axis is Critical for Efficacy of PRC2 Inhibitors in B‐Cell Lymphoma

Advanced Science
EZH2 is the catalytic subunit of the histone methyltransferase Polycomb Repressive Complex 2 (PRC2), and its somatic activating mutations drive lymphoma, particularly the germinal center B‐cell type.
Dongdong Liu, Zhen Li, Dongxia Tan, Yang An, Liping Chu, Tiancheng Chen, Weijia Li, Ailin Zhou, Ruijie Xiang, Liye Zhang, Yuxiu Qu, Wei Qi   +11 more
doaj   +1 more source

Unexpected Promotion of Bone Regeneration by Inhibition of BMPR1A‐Mediated BMP Signalling

Cell Proliferation, Volume 59, Issue 8, August 2026.
BMPR1A downregulation reduces ID1, releases TCF3 to activate GNG4‐PI3K‐AKT signalling, thereby promoting OPC proliferation and bone regeneration. ABSTRACT Bone morphogenetic protein (BMP) signalling plays a pivotal role in bone regeneration by regulating osteoprogenitor cell (OPC) function, and BMPs have been widely used in clinical treatment. However,
Zihao Zhou, Yun Zhai, Xiaochen Liu, Jiaojiao Shao, Jiani Zhou, Zhaoyang Li, Jiale He, Shuxian Lin, Qi Zhang   +8 more
wiley   +1 more source

Fibrodysplasia ossificans progressiva with minor unilateral hallux anomaly in a sporadic case from Northern Tanzania with the common ACVR1c.617G A mutation

The Pan African Medical Journal, 2015
Fibrodysplasia ossificans progressiva is a rare autosomal dominantly inherited disorder of connective tissue caused by mutations in the gene encoding for ACVR1/ALK2, a bone morphogenetic protein type I receptor.
Mohammed Saleh, Joost Commandeur, Renata Bocciardi, Grace Kinabo, Ben Hamel   +4 more
doaj   +1 more source

Chromosomal Instability Drives Glioblastoma Heterogeneity and Therapeutic Opportunities

Advanced Science, Volume 13, Issue 39, 13 July 2026.
ABSTRACT Glioblastoma, the most aggressive and lethal form of brain cancer, is defined by profound genomic instability, with Chromosomal Instability (CIN) playing a central role in driving tumor progression, therapy resistance, and poor prognosis. CIN is characterized by numerical and structural alterations, is driven by mechanisms such as mitotic ...
Amarnath Pal, Milan Patra, Rianita Mondal, Shubhasis Haldar   +3 more
wiley   +1 more source

Virus Titration And Test Expression Of Acvr1

, 2018
Test expression of ACVR1 using different virus levels to infect the insect cells. Purification of tests.
Adamson, Roslin, Brennan, Paul, Mateucci, Mizio, Bullock, Alex   +3 more
openaire   +1 more source

Pacritinib Impact on QT Interval: Results of a Thorough QT Study and Post Hoc Analysis of Prospective Clinical Trial Data

Clinical Pharmacology in Drug Development, Volume 15, Issue 6, June 2026.
Abstract Pacritinib, an inhibitor of JAK2/IRAK1/ACVR1 that is devoid of JAK1 activity, approved for treating myelofibrosis in patients with severe thrombocytopenia, carries a label warning for QT interval prolongation. To evaluate the cardiac safety of pacritinib, a randomized, placebo‐ and active‐controlled, single‐dose thorough QT (TQT) study was ...
Sarah A. Buckley, Suliman Al‐Fayoumi, James P. Dean, Jessica Zhang, Purvi Suthar, Muriel Richard   +5 more
wiley   +1 more source

Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma [PDF]

Nature Genetics, 2014
Pediatric midline high-grade astrocytomas (mHGAs) are incurable with few treatment targets identified. Most tumors harbor mutations encoding p.Lys27Met in histone H3 variants. In 40 treatment-naive mHGAs, 39 analyzed by whole-exome sequencing, we find additional somatic mutations specific to tumor location.
Adam M Fontebasso, Simon Papillon-Cavanagh, Jeremy Schwartzentruber, Hamid Nikbakht, Noha Gerges, Pierre-Olivier Fiset, Denise Bechet, Damien Faury, Nicolas De Jay, Lori A Ramkissoon, Aoife Corcoran, David T W Jones, Dominik Sturm, Pascal Johann, Tadanori Tomita, Stewart Goldman, Mahmoud Nagib, Anne Bendel, Liliana Goumnerova, Daniel C Bowers, Jeffrey R Leonard, Joshua B Rubin, Tord Alden, Samuel Browd, J Russell Geyer, Sarah Leary, George Jallo, Kenneth Cohen, Nalin Gupta, Michael D Prados, Anne-Sophie Carret, Benjamin Ellezam, Louis Crevier, Almos Klekner, Laszlo Bognar, Peter Hauser, Miklos Garami, John Myseros, Zhifeng Dong, Peter M Siegel, Hayley Malkin, Azra H Ligon, Steffen Albrecht, Stefan M Pfister, Keith L Ligon, Jacek Majewski, Nada Jabado, Mark W Kieran   +47 more
openaire   +4 more sources

Update On Fragment Screening Of Acvr1 Co_Crystallised With Ldn_193189

, 2018
The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no.
Adamson, Roslin, Matteucci, Mizio, Brennan, Paul, Bullock, Alex   +3 more
openaire   +2 more sources